![]() at Kumamoto University Graduate School of Medical Sciences in Japan. ![]() Enkhbaatar served as a Senior Lieutenant physician in the Mongolian Army. Following administration orally as a capsule, or nasally through use of a nasal spray, or by injection, R-107 releases nitric oxide systemically throughout the body.įollowing his medical training at the University of Saint Petersburg in Russia, Dr. Claritas is developing R-107 to supplement the body’s natural production of nitric oxide. However, a viral infection can spread more rapidly than the body can produce nitric oxide to combat the infection. Nitric oxide is part of the body’s natural defense system against viral infections. Enkhbaatar will be a strong strategic resource for Claritas, and we look forward to the contributions he will make.” Enkhbaatar and Cuzzocrea will help guide the Company’s development of R-107, our proprietary nitric oxide-releasing compound that is being developed as a treatment for coronavirus, COVID-19, and other viral infections. Cuzzocrea are internationally renowned authorities and leaders on the biology and pathophysiology of nitric oxide. “We previously announced the addition of Dr. Enkhbaatar to the Company’s Board enhances and strengthens our focus on nitric oxide pharmaceuticals,” stated Robert Farrell, President and CEO. Nitric oxide was named molecule of the year by Science magazine in 1992 over 130,000 peer reviewed articles have been published on the nitric oxide and nitric oxide was the subject of a 1998 Nobel Prize in medicine. Enkhbaatar is an internationally renowned authority and leader on the biology and pathophysiology of nitric oxide and acute lung injury, and his appointment to the Board of Directors will further strengthen the Company position as a leader in the field of nitric oxide therapeutics. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the " Company" or " Claritas") today announced the addition of Perenlei Enkhbaatar, MD, PhD, FAHA as an independent member of the Company’s board of directors (the “Board of Directors”), effective immediately.ĭr. ![]() SAN FRANCISCO and TORONTO, Ma(GLOBE NEWSWIRE) - Claritas Pharmaceuticals, Inc. Enkhbaatar’s Appointment Further Expands the Company’s Expertise in Field of Nitric Oxide Therapeutics ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |